Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official

MT Newswires Live

03/06

UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.

The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.

The company didn't immediately respond to a request for comment from MT Newswires.

Shares of the company were up 13% in Thursday trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 10.27, Change: +1.23, Percent Change: +13.61

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2617573380"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617573380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617573380?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 03:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617573380","market":"us","top_or_hot":-1,"title":"Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official","media":"MT Newswires Live","content":"<html><body><p> UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.</p><p>The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.</p><p>The company didn't immediately respond to a request for comment from MT Newswires.</p><p>Shares of the company were up 13% in Thursday trading.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 10.27, Change: +1.23, Percent Change: +13.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-06 03:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.</p><p>The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.</p><p>The company didn't immediately respond to a request for comment from MT Newswires.</p><p>Shares of the company were up 13% in Thursday trading.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 10.27, Change: +1.23, Percent Change: +13.61</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617573380","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617573380","pubTimestamp":1772740345,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UniQure's  experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.The company didn't immediately respond to a request for comment from MT Newswires.Shares of the company were up 13% in Thursday trading.Price: 10.27, Change: +1.23, Percent Change: +13.61","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","QURE":"uniQure N.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"市场热议：UniQure实验性治疗亨廷顿舞蹈症面临FDA官员批评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":1},"content_text":"UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.The company didn't immediately respond to a request for comment from MT Newswires.Shares of the company were up 13% in Thursday trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 10.27, Change: +1.23, Percent Change: +13.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}